The French pharmaceutical company filed the lawsuit on 8 August in the US District Court for the District of New Jersey after Merck filed its New Drug Application with the FDA for an insulin glargine vial drug product called Lusduna Nexvue.
In its application, Merck challenged all of the Sanofi patents listed in the FDA’s Orange Book for its Lantus and Lantus SoloStar diabetes drugs.
Lantus helps diabetics control blood sugar levels.
In 2014, Sanofi sued Eli Lilly over its Lantus patents, accusing it of infringing seven patents.
Lily agreed to pay Sanofi royalties, settling the case.